Novogen (NVGN) Presents At 29th Annual ROTH Conference

Stock Information for Novogen Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Novogen Limited

Australian cancer specialists may hold key to next advancement in ovarian cancer treatment
GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
Board Review of Business Operations and Governance
Progress Update on Cantrixil(TM) (TRXE-002-1) Development
Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure
Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program
Conversion of Convertible Notes
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.